Anondita Medicare Limited has provided the audio recording link for its earnings conference call held on May 27, 2026, at 4:00 P.M. IST. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording is now available on the company's official website for public access.

The conference call was conducted to discuss the financial performance of the company. During the interaction, the management confirmed that no unpublished price sensitive information (UPSI) was shared. The update serves as a continuation of the company's previous intimation dated May 27, 2026, regarding the outcome of the call.

The table below summarizes the key details of the event:

The disclosure was submitted to the National Stock Exchange of India Limited by Bhawna Bisht, Company Secretary and Compliance Officer. Anondita Medicare Limited operates as a manufacturer of condoms and holds ISO 9001:2015, ISO 13485:2016, and CDSCO certifications.

Anondita Medicare Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with a 108% year-on-year surge in profit after tax (PAT) to ₹3,429.65 lakh. Revenue from operations grew 78% to ₹13,741.57 lakh, while EBITDA increased 100% to ₹5,150.85 lakh, driven by operational efficiency and market penetration. The strong momentum continued in the second half, with H2 FY26 PAT rising 103% to ₹2,127.86 lakh and revenue increasing 83% to ₹8,331.87 lakh.

The board approved the audited standalone and consolidated financial results on May 22, 2026. The company submitted the Integrated Filing (Financial) to the National Stock Exchange of India under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors provided an unmodified opinion on the consolidated results.

Financial Highlights

The following table summarizes the key financial figures for FY26 compared to the prior year:

For the six months ended March 31, 2026, the EBITDA margin expanded to 38.29% from 35.02% in H2 FY25, an increase of 327 basis points. The PAT margin for the period improved to 25.54% from 22.98%.

Operational Performance

Total income for FY26 stood at ₹13,825.81 lakh, with total expenses amounting to ₹9,136.85 lakh. The basic and diluted earnings per share (EPS) for the year were recorded at ₹21.3. Total shareholders' funds as of March 31, 2026, were reported at ₹12,923.58 lakh.

Mr. Anupam Ghosh, Managing Director, attributed the growth to capacity enhancement and expanding international presence. The company operates its flagship brand "COBRA" and is focused on automation-led capacity enhancement and innovative patented female condom products.